A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from ...

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years.